Antev Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 5

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5.41M

Antev General Information

Description

Operator of the biopharmaceutical firm intended to overcome the historical problems of GnRH (gonadotropin-releasing hormone) in antagonist candidates. The company specializes in the development of therapies in areas including prostate cancer, benign prostatic hyperplasia, and acute urinary retention, along with women's health indications such as endometriosis and uterine fibroids, enabling clients from the healthcare industry to focus on the unmet clinical need for health and develop drugs easily.

Contact Information

Website
www.antev.co.uk
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 106 New Bond Street
  • 3rd Floor
  • London W1S 1DN
  • England, United Kingdom
+44 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Corporate Office
  • 106 New Bond Street
  • 3rd Floor
  • London W1S 1DN
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antev Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 29-Aug-2025 $5.41M Completed Clinical Trials - Phase 2
3. Later Stage VC 10-Apr-2024 Completed Clinical Trials - Phase 2
2. Seed Round 13-Apr-2019 $1.86M $2.93M Completed Clinical Trials - Phase 1
1. Seed Round 21-Sep-2017 $1.07M $1.07M Completed Clinical Trials - Phase 1
To view Antev’s complete valuation and funding history, request access »

Antev Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 189,484 $0.012669 $5.45 $5.45 1x $5.45 6.41%
To view Antev’s complete cap table history, request access »

Antev Patents

Antev Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025229186-A1 Composition for use in reducing the risk of recurrent acute urinary retention Pending 03-May-2024
EP-4643869-A1 Use of gnrh antagonists such as teverelix to treat acute urinary retention Pending 03-May-2024
EP-4541365-A1 Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer Inactive 18-Oct-2023
EP-4794710-A1 Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer Pending 18-Oct-2023
WO-2025083070-A1 Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer Inactive 18-Oct-2023 A61K38/09
To view Antev’s complete patent history, request access »

Antev Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antev Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
S&W (London) PE-Backed Company Minority
To view Antev’s complete investors history, request access »

Antev Investments (1)

Antev’s most recent deal was a Corporate Asset Purchase with LifeArc (Intellectual Property Rights for Teverelix). The deal was made on 01-Jan-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
LifeArc (Intellectual Property Rights for Teverelix) 01-Jan-2014 Corporate Asset Purchase Buildings and Property
To view Antev’s complete investments history, request access »

Antev FAQs

  • When was Antev founded?

    Antev was founded in 2013.

  • Where is Antev headquartered?

    Antev is headquartered in London, United Kingdom.

  • What is the size of Antev?

    Antev has 5 total employees.

  • What industry is Antev in?

    Antev’s primary industry is Drug Discovery.

  • Is Antev a private or public company?

    Antev is a Private company.

  • What is the current valuation of Antev?

    The current valuation of Antev is .

  • What is Antev’s current revenue?

    The current revenue for Antev is .

  • How much funding has Antev raised over time?

    Antev has raised $14M.

  • Who are Antev’s investors?

    S&W (London) has invested in Antev.

  • When was Antev acquired?

    Antev was acquired on 29-Aug-2025.

  • Who acquired Antev?

    Antev was acquired by Medicus Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process